Acute Myeloid Leukemia (AML) develops due to the acquisition of mutations from multiple functional classes. Here, we demonstrate that activating mutations in the granulocyte colony stimulating factor receptor (CSF3R), cooperate with loss of function mutations in the transcription factor CEBPA to promote acute leukemia development. This finding of mutation-synergy is broadly applicable other mutations that activate the JAK/STAT pathway or disrupt CEBPA function (i.e. activating mutations in JAK3 and Core Binding Factor translocations). The interaction between these distinct classes of mutations occurs at the level of myeloid lineage enhancers where mutant CEBPA prevents activation of subset of differentiation associated enhancers. To confirm this enhancer-dependent mechanism, we demonstrate that CEBPA mutations must occur as the initial event in AML initiation, confirming predictions from clinical sequencing data. This improved mechanistic understanding will facilitate therapeutic development targeting the intersection of oncogene cooperativity.
INTRODUCTION
Acute Myeloid Leukemia (AML) is a deadly hematologic malignancy that results from the stepwise acquisition of genomic aberrations. The mutations that collaborate to produce AML often occur in distinct functional categories 1 . Class I mutations activate signaling pathways and in isolation produce disease with a myeloproliferative phenotype. Class II mutations perturb the function of transcription factors or epigenetic modifiers and alone can cause a myelodysplastic phenotype. However, when present in combination, Class I and Class II mutations produce a highly proliferative disease with a block in differentiation, both hallmarks of AML.
The transcription factor CCAAT enhancer binding protein alpha (CEBPA) is the master regulator of myeloid lineage commitment. CEBPA is recurrently mutated in AML and is a classic example of a class II mutation 2 . Mutations in CEBPA cluster at the N-and Cterminus of the protein. N-terminal mutations disrupt CEBPA-dependent cell cycle regulation while C-terminal mutations occur in the DNA-binding domain and produce dominant negative loss of function. Recent studies have identified a high rate of cooccurrence of mutations in CEBPA with mutations the granulocyte-colony stimulating factor receptor (CSF3R) [3] [4] [5] [6] . CSF3R mutations most commonly occur in the membrane proximal region, and lead to ligand independent receptor dimerization and constitutive signaling via the JAK/STAT pathway. Similar to other Class I mutations, membrane proximal CSF3R mutations produce a myeloproliferative phenotype when present in isolation and are the major oncogenic driver of the disease chronic neutrophilic leukemia 7 . During normal myeloid development, G-CSF signaling via CSF3R leads to proliferation of myeloid precursors and neutrophilic differentiation. CEBPA is required for CSF3R-mediated transcription of myeloid specific genes, and myeloid differentiation arrests at the level of the common myeloid progenitor when CEBPA is deleted 8, 9 . In patients harboring both CEBPA and CSF3R mutations, prognosis is worse than when mutant CEBPA is present in isolation 10 . In spite of the established functional interdependence of CSF3R and CEBPA during normal hematopoiesis, the mechanism by which oncogenic mutations in these two genes drive AML remains unknown.
Herein, we demonstrate that CSF3R and CEBPA cooperate to produce a highly proliferative immature myeloid leukemia in mice that phenocopies the human disease transcriptionally and morphologically. We establish that mutant CSF3R exerts much of its activity through the binding of the STAT family of transcription factors to promoters. In contrast mutant CEBPA exerts little oncogenic activity at promoters, instead impacting the activation of differentiation associated enhancers. We further demonstrate that mutant CEBPA must occur prior to mutant CSF3R in order for AML to initiate. This confirms predictions based on clinical sequencing and provides a novel model to study oncogene order.
RESULTS

CSF3R
T618I and CEBPA Mutations Cooperate to Produce Rapid Cell Growth We decided to study a representative N-terminal and C-terminal mutation (F82fs and V314VW), in combination with CSF3R mutations, which frequently co-occur in AML 4 . When expressed in mouse bone marrow cells via retroviral transduction, neither CEBPA F82fs nor CEBPA V314VW produced colonies in cytokine free methylcellulose ( Figure 1A , B). As previously reported, CSF3R
T618I produced a modest number of colonies in isolation 7 . The addition of CEBPA V314VW , but not CEBPA F82fs , dramatically augmented CSF3R
T618I
-driven colony production, produced indefinite replating, and supported sustained growth in liquid media lacking cytokines ( Figure 1C ). These results were confirmed with a second C-terminal CEBPA mutation CEBPA K313KR ( Figure 1D ). To determine how co-expression of both N-and C-terminal CEBPA mutations would alter the effects of CSF3R T618I , we expressed all three mutations simultaneously. In this context, the addition of CEBPA F82fs mildly augmented CFU formation beyond that seen with CSF3R T618I and CEBPA V314VW ( Figure 1E , F). To determine whether this phenomenon was generalizable, we looked for other mutations that co-occur with CEBPA in AML. We identified a patient from a recently published data set with CEBPAmutant AML who also had a previously characterized activating Class I mutation in JAK3 (JAK3 M511I ) 11, 12 . Simultaneous introduction of these mutations promoted cytokine independent colony growth in vitro ( Figure 1G ,H). CSF3R mutations also co-occur with the chromosomal translocation t (8;21) , leading to expression of the AML-ETO oncoprotein 4 . Similar to mutations in CEBPA, AML-ETO also augmented CSF3R T618I -induced colony formation ( Figure 1I , J). AML-ETO is known to down-regulate CEBPA, possibly providing a unifying mechanism for oncogenic cooperation with activated JAK/STAT signaling 13 . Consistent with this, we found that expression of AML-ETO in mouse bone marrow resulted in a decrease in CEBPA expression ( To characterize gene expression changes driven by CSF3R T618I and CEBPA
V314VW
, we performed RNA-seq on mouse bone marrow transduced with CSF3R T618I , CEBPA V314VW , or the combination of both. We used a linear model with an interaction term ( Figure 2A) , and identified 683 genes that were significantly up or down regulated in response to CSF3R T618I (q <0.05, Log2 fold change >1 or <-1). We also identified 809 genes up or down regulated in response to CEBPA V314VW expression. Additionally, there were 570 genes that demonstrated an interaction between CSF3R T618I and CEBPA V314VW (effect less or more than additive). To identify enriched transcriptional programs, we performed Gene Set Enrichment Analysis (GSEA) comparing CSF3R T618I to all other conditions (Figures 2B, Figure S1A ). CSF3R T618I dramatically up-regulated genes associated with myeloid differentiation, while CEBPA V314VW strongly downregulated them. In addition, genes associated with the wild type CEBPA network followed a similar pattern ( Figure 2C ). This suggests that myeloid differentiation in response to CSF3R
T618I is, at least in part, dependent on CEBPA.
To further describe the transcriptional changes associated with concurrent oncogene expression, we performed hierarchical clustering of the interacting genes ( Figure 2D & Table S1 ). Of particular interest was a cluster of genes that were strongly up-regulated by CSF3R
T618I
, but suppressed by co-expression of CEBPA
V314VW
, as this mirrored the pattern of myeloid differentiation. This cluster contained genes such as Nos2, Hck, Stf1a, and Pla2g7, all of which are expressed in mature neutrophils 14 . To determine, whether CEBPA binding was significantly associated with these interacting genes, we analyzed published ChIP-seq data from mouse granulocyte-macrophage progenitors (GMPs) 15 and showed that 60% of the interacting genes were within 2 Kb of a CEBPA peak, compared with approximately 20% of non-interacting genes ( Figure S1C ). We next performed motif enrichment analysis at the promoters of each category of differentially expressed genes ( Figures 2E & S1B ). This identified a strong enrichment of STAT binding sites in the promoters of CSF3R T618I up-regulated genes. Surprisingly however, we did not detect CEBPA motif enrichment at the promoters of any of the groups of DE genes, suggesting that CEBPA V314VW may impact CSF3R
T618I
-induced myeloid differentiation through binding to non-promoter regulatory regions.
To validate these findings in human AML, we examined RNA-seq data from the pediatric TARGET initiative 16 . A total of 152 patients were evaluated, including seven patients with CEBPA mutations, and 2 patients with both CSF3R and CEBPA mutations. Differential gene expression revealed markedly decreased HOX gene expression in CEBPA mutant samples compared with CEBPA WT samples, a wellestablished finding in adult CEBPA mutant AML ( Figure 2F , Table S2 ) 17 . Interestingly, CSF3R mutant samples tended to display increased HOX gene expression although this did not rise to the level of statistical significance. Comparison of CEBPA mutant/CSF3R WT and CEBPA mutant/CSF3R mutant patient samples revealed numerous differentially-expressed genes (Table S2) . Principle component analysis using these differentially-expressed genes clearly separates CEBPA/CSF3R mutant samples from those harboring mutant CEBPA alone ( Figure S1D ). Comparison of these differentially-expressed genes to those identified in mouse revealed 52 ortholog pairs with differential expression driven by mutant CSF3R ( Figure 2G ). Of these, 75% demonstrated concordant regulation between mouse and human. A similar analysis was performed on adult CEBPA/CSF3R mutant AML samples from the Leucegene cohort, which also demonstrated that the preponderance of orthologous gene pairs display concordant regulation ( Figure 2I ) 3 . Both human/mouse concordant gene sets were able to independently segregate CSF3R mutant from wild type samples by PCA ( Figure 2H , J).
JAK/STAT Activation and CEBPA Dysregulation Cooperate to Promote Myeloid Leukemia in vivo
To establish whether oncogenic CSF3R and CEBPA mutations collaborate in vivo to produce AML, we performed murine bone marrow transplantation with retrovirally introduced CSF3R T618I alone or in combination with CEBPA V314VW or CEBPA F82fs . Mice receiving cells transduced with CSF3R T618I and CEBPA V314VW developed a myeloid leukemia that was uniformly lethal by day 14 post-transplant and was associated with leukocytosis and marked splenomegaly ( Figures 3A-B , F-G & Figure S2A ). In the bone marrow, normal hematopoiesis was completely replaced by large cells with myeloblastic morphology (Figures 3C, S2B-D) . The blasts were positive for CD11b, but were dim for GR-1 relative to the CD11b+/GR-1 high cells seen in CSF3R T618I alone mice sacrificed at an early time point ( Figure 3D ). The CSF3R/CEBPA mutant leukemia was also amenable to serial transplant in up to quaternary recipients ( Figure S3A-C) . Mice harboring CSF3R
T618I alone or in combination with CEBPA F82fs developed disease with a long latency, associated with leukocytosis, variable splenomegaly, mature immunophenotype, and morphologic neutrophils in the peripheral blood and bone marrow (Figures 2A-B , & S3D-H). Similarly, the combination of JAK3 M511I with CEBPA V314VW also produced a rapidly lethal myeloid leukemia with markedly reduced latency compared with expression of either mutation alone ( Figure 3H -J). In addition, the combination of AML-ETO and CSF3R
T618I also produced an accelerated undifferentiated myeloid leukemia ( Figure 3K-M) . Collectively, these data show that activation of JAK-STAT signaling and disruption of CEBPA are sufficient to drive leukemia development with all the cardinal features of AML.
CEBPA Mutations Disrupt Activation of Myeloid Lineage Enhancers
During normal hematopoietic development, CEBPA is responsible for establishing the enhancer landscape that permits myeloid differentiation 18 . We therefore hypothesized that CEBPA V314VW blocks differentiation by inhibiting priming or activation of myeloid lineage enhancers. To test this, we utilized murine HoxB8-ER cells, which mimic GMPs and differentiate down the neutrophilic lineage to become CD11b and GR-1 positive after estrogen withdrawal 19 . In this model, expression of CSF3R T618I accelerated differentiation, while CEBPA V314VW blocked differentiation, as measured by CD11b and GR-1 expression (Figures 4A & S4A) . The combination of mutations produced maturation arrest, similar to CSF3R/CEBPA mutant murine leukemia. We confirmed that neither oncogene was changing the expression of the other by qPCR ( Figure S4B) . A similar differentiation-block was seen when AML-ETO was co-expressed with CSF3R T618I ( Figure S4C ). Thus, HoxB8-ER cells expressing CSF3R T618I and CEBPA V314VW recapitulate the phenotype seen in our in vivo model.
To study enhancer dynamics in the context of these mutations, we performed chromatin immunoprecipitation sequencing (ChIP-seq) for H3K4me1, H3K4me3 and H3K27ac in HoxB8-ER cells transduced with CSF3R   T618I   , CEBPA   V314VW , both mutations, or empty vectors. We identified 42,124 active enhancers (defined as high H3K4me1, low H3K4me3 and high H3K27ac) across all 4 conditions (Table S4 ). To validate these findings in human AML, we mapped our enhancers to orthologous human genomic coordinates and assessed overlap of enhancers only active in the CSF3R T618I /CEBPA V314VW condition with those present in human AML with mutant CEBPA 20 . We observed a significant enrichment of overlap between our mouse AML enhancers with those found in human AML, suggesting conserved biology ( Figure S5D ). We performed a similar analysis using regions of DNase I hypersensitivity from human CEBPA mutant AML and again saw marked enrichment ( Figure S5E ).
We next focused on enhancers that were active exclusively in one condition (ConditionSpecific Enhancers, Figures 4B, C & S5A-C ). An example of a CSF3R T618I -specific enhancer in proximity to the Nos2 gene is shown ( Figure 4D ). Gene ontology analysis on the 2,237 CSF3R T618I -specific enhancers revealed enrichment for terms associated with immune responses and phagocytosis, demonstrating that these genes are associated with the mature neutrophil phenotype ( Figure 4E , Table S5 ). To understand whether CEBPA V314VW blocks myeloid differentiation through disruption of CSF3R T618I -specific enhancers and associated gene expression, we performed microarray gene expression analysis on HoxB8-ER cells harboring each oncogene in isolation or the combination ( Figure 4F , Table S3 ). The expression profiles of key genes were validated by qPCR ( Figure S5B ). Genes associated with mature myeloid phenotypes, such as Nos2, Hck, Bcl6 and Pla2g7, displayed increased expression in the CSF3R T618I condition, and were repressed with co-expression of CEBPA
V314VW
. To globally assess whether CSF3R target genes were associated with CSF3R T618I -specific enhancers, we performed hierarchical clustering on genes that were differentially expressed in one or more treatment condition. We then examined enrichment of each condition-specific enhancer group across these clusters ( Figure 4F , Table S3 ). Specifically, we observed strong enrichment of CSF3R T618I -specific enhancers in Clusters 1 and 4, which displayed the highest level of gene expression with CSF3R T618I alone.
In contrast with enhancer activation, there was little difference in enhancer priming (as denoted by presence/absence of H3K4me1 peaks) across the four treatment conditions. However, the intensity of H3K4me1 signal at CSF3R
T618I
-specific enhancers varied between conditions. H3K4me1 enrichment at CSF3R T618I -specific enhancers was strongest in cells expressing CSF3R T618I only, and lowest in cells expressing CEBPA V314VW only ( Figure 4G ). To quantify this, we identified regions with significantly different H3K4me1 enrichment between CSF3R T618I and CEBPA V314VW conditions. This analysis revealed 798 regions of H3K4me1 that were specific to CSF3R T618I and 833 regions specific to CEBPA V314VW . Regions with higher H3K4me1 enrichment in CSF3R T618I were highly associated with enhancers that were specifically activated by CSF3R T618I . In contrast, regions with higher H3K4me1 enrichment in the CEBPA V314VW condition were associated with CEBPA V314VW -specific enhancers. This demonstrates that in addition to regulating enhancer activation, CSF3R T618I and CEBPA V314VW also affect H3K4me1 levels.
To identify possible transcriptional regulators, we performed transcription factor motif enrichment. This analysis demonstrated enrichment of CEBPA motifs in CSF3R T618I -specific enhancers, but not in any other group ( Figure 4H ). This suggests that CEBPA V314VW blocks differentiation by disrupting the interaction of wild type CEBPA with CSF3R T618I -specific enhancers. To provide further evidence for this hypothesis, we utilized published CEBPA ChIP-seq data from GMPs (the nearest normal cell to HoxB8 immortalized progenitors) 15 . We found strong enrichment of CEBPA peaks overlapping CSF3R T618I -specific enhancers, but not the other condition-specific enhancer groups ( Figure 4I ). These data support a model in which CEBPA V314VW displaces wild type CEBPA from CSF3R T618I -specific enhancers, preventing enhancer activation and subsequent expression of differentiation-associated genes.
CEBPA Mutations Must Precede Mutations in CSF3R for AML Initiation
Enhancer priming and activation precede promoter activation, suggesting that epigenetic changes at enhancers must occur as early events 21 . Clinical sequencing data demonstrates that CEBPA mutations frequently occur at higher variant allele frequencies than CSF3R mutations 3, 4 . This has led to the prediction that CEBPA mutations occur early in disease development. Conversely however, it is possible that CEBPA mutations could be acquired late during blast-crisis transformation of chronic neutrophilic leukemia. To evaluate the impact of mutation order on AML development, we developed a Cre-inducible retroviral vector. We paired this vector with hematopoietic cells from Rosa 26
ERT2
-Cre, which is activated via tamoxifen administration ( Figure 5A ). We co-expressed this inducible vector with a constitutive vector, enabling the study of two distinct mutational orders of acquisition: CSF3R T618I first and CEBPA V314VW first. We first assessed the impact of mutation order on bone marrow colony formation by plating both ordered combinations in the presence of 4-hydroxytamoxifen (4-OHT), thus delaying the expression of the second oncogene by approximately 48 hours. Strikingly, we found that CSF3R -first mouse developed leukemia at 7 weeks post-tamoxifen administration. Bone marrow cytology revealed a blast-like morphology, however flow cytometry revealed increased GR-1 staining, indicative of a higher degree of myeloid maturation ( Figure 6C ). Collectively, these data reveal that when CEBPA mutations are introduced after mutations in CSF3R, they are unable to fully block myeloid differentiation. Importantly, this impaired ability to block differentiation disrupts the development of AML in vivo.
DISCUSSION
Our study adds to a growing body of data demonstrating that enhancer biology is integral to the development of hematologic malignancies. While AML is very heterogeneous from a genomic standpoint, recent work demonstrates that there are only a few epigenetic disease subtypes 20, 26 . Thus, understanding the epigenetic dysfunction in AML may provide broad insight into therapeutic approaches. Although multiple global epigenetic regulators are recurrently mutated in AML, these have little impact on the organization of the epigenome 20, 26 . Instead, mutations in lineage determining transcription factors are a major determinant of clustering. Using a DNase-I sequencing approach, Assi et al recently showed that core binding factor translocations and CEBPA mutant AML cluster together, consistent with our findings here of shared biology between AML-ETO and CEBPA 26 .
Although we focused on differentiation-associated enhancers driven by the CSF3R T618I , our study revealed a second set of enhancers that were activated exclusively in the presence of both mutant CSF3R and CEBPA. Both subsets of enhancers demonstrated strong enrichment of PU.1 motifs, consistent with the known role of this transcription factor in driving myeloid development. In normal hematopoiesis, PU.1 and CEBPA cooperate to open myeloid lineage enhancers with PU.1 performing pioneering function in early progenitors and CEBPA assuming this role late 18 . Thus, it is likely that certain early myeloid lineage enhancers can be activated by CSF3R T618I in a CEBPAindependent manner via PU.1. Another interesting finding was the enrichment of RUNX motifs in enhancers activated only in the presence of both oncogenes. The RUNX family of transcription factors are critical to normal hematopoietic development, and in addition to being the targets of chromosomal translocations in core binding factor AML, also frequently harbor point mutations in AML 27 . Interestingly, Runx1 haploinsufficiency leads to hypersensitivity to GCSF, suggesting a negative feedback role 28 . The role of RUNX transcription factors in driving CEBPA/CSF3R mutant AML is an interesting area for future work.
We present the first direct evidence that the order in which oncogenic mutations occur is a major determinant of leukemia development ( Figure 7G ). Our finding that myeloid differentiation blockade can only occur with a distinct mutational order may also be a broadly conserved mechanism that applies to Class I and Class II mutation pairings. As nearly all prior studies have investigated mutation cooperation in the setting of simultaneous introduction, it is likely that important aspects of order-dependent disease biology have not yet been discovered. If reprograming of the lineage-specific enhancer repertoire is a common initiating event in AML, this creates even more impetus for the development of treatment strategies targeting these epigenetic pathways.
Our finding that epigenetic dysfunction is an obligate early event is likely to be generalizable to other forms of cancer. In renal cell carcinoma, loss of the tumor suppressor von Hippel-Lindau (VHL) is widely regarded as an initiating event and associated with dramatic changes in global DNA methylation, potentially impacting subsequently acquired signaling mutations 22 . In breast cancer, mutation order is an important determinant of cancer phenotype, with luminal-type tumors demonstrating early loss of PTEN while basal-type tumors display early p53 mutation 23 . In colon cancer, the canonical APC mutations decrease DNA methylation through upregulation of demethylases, which no doubt alter the impact of RAS mutations acquired later in disease evolution 24 . Order-dependent mutational phenotypes were recently reported in myeloproliferative neoplasms, where the order of mutations in JAK2 and TET2 are important determinants of disease phenotype 25 . When TET2 precedes JAK2, patients are more likely to present with polycythemia vera. In contrast, patients with JAK2-first disease were more likely to have essential thrombocytosis. Thus, it appears that preceding TET2 mutation provides an epigenetic context supporting erythroid development for subsequently-acquired JAK2 mutations.
In summary, we describe the epigenetic mechanism by which mutant CEBPA and CSF3R interact to drive AML development. Our study demonstrates that a subset of differentiation-associated enhancers are dysregulated by mutant CEBPA preventing normal myeloid maturation. Critically, this epigenetic dysregulation must occur as the initial event otherwise AML does not develop. These differentiation-associated enhancers represent a promising novel therapeutic target in this poor prognosis molecular subtype of AML. T618I and CEBPA V314VW compared with mice receiving 100,000 cells transduced with CSF3R
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T618I and empty vector (At this time point, control mice had recovered from transplant-induced pancytopenia allowing direct comparison, same cohort as Figure 3C -G, n=3/group). E. Representative bone marrow flow cytometry for myeloid maturation and stem/progenitor cell populations from mice transplanted with CSF3R T618I + Empty vector or CSF3R T618I + CEBPA F82fs at survival endpoint (Same cohort as Figure 3A , B, representative of 3 animals/group). F. Hemoglobin concentration over time in mice from Figure 2A , B. G. Platelet count over time in mice from Figure 3A , B. H. Spleen weight from mice in Figure 3A , B). Cell Lines 293T17 cells were obtained from ATCC and cultured in RPMI (Gibco) with 20% fetal calf serum (FCS, HyClone). Murine HoxB8-ER cells were a generous gift from David Sykes (Massachusetts General Hospital, Boston, MA) and cultured in RPMI (Gibco) with 10% FCS and CHO-SCF cell conditioned media (final concentration ~100 ng/mL) 27 . Wild type HoxB8-ER cells were cultured and differentiated as previously described 19 . Cell lines were tested monthly for mycoplasma contamination.
Cloning and Retrovirus Production
The following plasmids were utilized: pMSCV-IRES GFP 7 , pMXs-IRES-Puro (Cell Biolabs Inc), pMSCV-IRES-mCherry FP (a gift from Dario Vignali, Addgene #52114), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE (a gift from Hans Clevers, Addgene #32702). The CSF3R T618I mutation was generated previously 7 . Full-length CEBPA and JAK3 cDNA was obtained from Genecopia. The CEBPA and JAK3 mutations were generated using the Quikchange Site Directed Mutagenesis Kit (Agilent) using the primers in Table S7 . Mig containing AML-ETO was a gift from Dong-Er Zang, (Addgene #12434). To produce retrovirus, 293T17 cells were transfected with EcoPac helper plasmid (a gift from Dr. Rick Van Etten), and the appropriate transfer plasmid. Conditioned media was harvested 48-72 hours after transduction.
Retroviral Transduction
Retroviral transduction of mouse bone marrow was performed as previously described 7, 29 . For colony assay, 2500 sorted cells were used per replicate. For bone marrow transplantation experiments, 200,000 cells were administered, with the balance of nontransduced cells as fresh syngeneic bone marrow. Survival endpoints for mutation comparison studies included WBC count>100, weight loss>20% initial weight, and moribund appearance.
Real Time PCR
RNA was extracted using RNeasy or RNeasy micro kit (Qiagen). cDNA was synthesized using a High Capacity cDNA Synthesis kit (ThermoFisher). Real time PCR was performed using the QuantSudio7 Real Time PCR System (ThermoFisher) and Taqman primer probes (Thermofisher). For Taqman low-density arrays, array cards were custom printed by the manufacturer (ThermoFisher). Taqman primer probes used in this study are listed in Table S8 .
Flow Cytometry
The antibodies listed in Table S9 were utilized for FACS according to the manufacturer instructions. Stained cells were analyzed on a FACSAria III flow cytometer (BD).
RNA Sequencing
Bone marrow from C57BL/6 mice was harvested and retrovirally transduced with the indicated oncogene combinations as described above. Cells were stained with a lineage cocktail, and lineage negative GFP/mCherry-double-positive cells were sorted. For order of acquisition experiments, cells were cultured in cytokine free I20 media for 48 hours after sorting in the presence of 500 nM 4-Hydroxytamoxifen. RNA was extracted using the RNeasy micro kit (Qiagen). cDNA libraries were constructed using the SMARTer universal low input RNA kit (Clonetech) and sequenced using a HiSeq 2500 Sequencer (Illumina) 100bp SR.
Microarray
Labeled target, sscDNA was prepared from 12 RNA samples using the GeneChipTM WT-Plus protocol (ThermoFisher). Prior to cDNA synthesis and amplification, sample order was randomized. Amplified and labeled cDNA target samples were hybridized to a GeneChip Clariom S-Mouse array (ThermoFisher). Image processing was performed using Affymetrix Command Console (AGCC) v.3.1.1 software and expression analysis was performed using Affymetrix Expression Console. Differential Expression analysis was performed using the Transcript Analysis Console 4.0 (ThermoFisher). ) were fixed with 1% formaldehyde and quenched by glycine. Cells were resuspended in lysis buffer (0.1% SDS, 0.5% Triton X-100, 20 mM Tris-HCl pH=8.0, 150 mM NaCl, 1x Proteinase inhibitor (Roche)), and sheared using the Bioruptor Pico sonicator (Diagenode). Reactions were rotated overnight at 4°C with antibody (H3K4me1 (ab8895, Abcam), H3K4me3 (ab8580, Abcam) andH3K27ac (ab4729, Abcam), Table S10 ). Next, samples were rotated with Protein A/G Magnetic Beads (Pierce). Beads were washed with TBST buffer (3x), lysis buffer, and 2xTE pH=8. Chromatin was eluted at room temperature in 1% SDS, 0.1 M NaHCO3. Crosslinks were reversed at 65°C overnight, digested with RNAse A and proteinase K, then purified by phenol-chloroform extraction. Sequencing libraries were generated using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England Biolabs). Libraries were sequenced using SE 75 bp Illumina NextSeq.
Chromatin-Immunoprecipitation
Bioinformatic Analysis
RNA-seq Analysis: Murine Samples
Raw reads were trimmed with Trimmomatic 30 and aligned with STAR 31 . Differential expression analysis was performed using DESeq2 32 . Raw p values were adjusted for multiple comparisons using the Benjamini-Hochberg method.
RNA seq Analysis: TARGET Pediatric AML Samples
RNA sequencing was performed on RNA collected from Pediatric AML samples as described in the initial TARGET AML publication 33 . Raw reads were aligned with Kallisto with count tables produced using Tximport 34, 35 . Differential expression analysis was performed using DESeq2 32 . Raw p-values were adjusted for multiple comparisons using the Benjamini-Hochberg method. For comparison with mouse RNA seq, genes with differential expression between CSF3R WT and CSF3R T618I were mapped to orthologous human genes using ensembl BioMart. Genes with differential expression in both mouse and human were considered and compared by Log2 Fold change between CSF3R mutant and CSF3R WT conditions.
Convergent Gene Expression Analysis: Leucegene AML
RPKM values from adult AML samples from the Leucegene cohort were downloaded using the following SRA accession numbers: GSE49642, GSE52656, GSE62190, GSE66917, GSE67039. Mouse genes with differential expression driven by CSF3R
T618I
were converted to human gene symbols as above. Genes demonstrating an absolute fold change of >2 in both datasets were compared by Log2 Fold change between CSF3R mutant and CSF3R WT conditions.
Motif Enrichment Analysis
The enrichment analysis for motifs was performed using HOMER 36 using thefindMotifs command in a 500 bp window upstream and 200 bp downstream of the transcriptional start site. De novo motifs at enhancers were identified using thefindMotifsGenome command in HOMER in a +/-1000 bp region surrounding the peak center. De novo motifs were matched to their closest known motif and displayed with the alignment score (with 1 being a perfect match). Top 5 motifs with p< 1E-10 for each group of promoters or enhancers are displayed.
Gene Set Enrichment Analysis
Gene set enrichment analysis using the GSEA software as previously described 37 . As CSF3R T618I -only and CSF3R
T618I
-first groups clustered together by Euclidian distance, they were combined and compared with CEBPA V314VW -first samples. Analysis was performed using the C2 collection from MSigDB. Permutations were performed by gene set and significance was set as an FDR adjusted p value of <0.05.
Permutation Analysis
CEBPA ChIP-seq peaks from GMPs 15 were converted from the mm9 to mm10, using the liftOver tool from the UCSC genome browser. We used BEDTools 38 to randomly shuffle the location of all interacting genes, within their original chromosomes. After each shuffle, we used the closest-features subcommand in BEDOPS 39 to calculate the distance between the new position of all shuffled genes and the closest CEBPA ChIPseq.
ChIP-seq Analysis
Reads were aligned to the mouse reference genome (mm10) using bwa 0.7.12 40 with default single end settings. Low mapping alignments were removed with samtools (MAPQ<30) 41 . Next, MACS2 2.1.1 42 was used to predict significant peaks of ChIP-seq enrichment relative to the appropriate input controls and generate fold enrichment tracks. We used the ChromHMM software 43 to characterize and annotate the genomes of each treatment group according to 6 chromatin states, based on different combinations of H3K4me1, H3K4me3 and H3K27ac marks. Enhancers were identified through the presence of H3K4me1 and H3K27Ac, absence of H3K4me3. Enhancers less than 500bp apart were merged. The closest gene to each enhancer was identified using BEDOPS 39 . In order to remove potential false positives due to proximity to large H3K27ac peaks, we removed treatment-specific putative enhancers without a H3K27ac peak summit.
Gene Ontology Analysis for ChIP-seq
Gene Ontology Analysis for histone mark ChIP-seq performed by Genomic Regions Enrichment of Annotations Tool 44 using the basal plus extension model to annotate enhancer coordinates with nearby genes.
Correlation of Gene Expression with Enhancer Activation
All differentially expressed genes as assessed by microarray analysis utilized for unsupervised hierarchical clustering analysis with a k-means=8. Each active enhancer was then annotated to the nearest gene. Condition-specific enhancers associated with each cluster of differentially expressed genes were counted and enrichment assessed as described under statistics.
H3K4me1 Differential Enrichment Analysis
To assess differences in levels of H3K4me1 across treatments, we used MACS2 bdgdiff subcommand 42 to compare levels of H3K4me1 enrichment between the CSF3R T618I and CEBPA V314VW treatments. We set the minimum length of a region differentially enriched in H3K4me1 signal at 300 bp and merged differentially enriched regions less than 250 bp apart. Each region of differential H3K4me1 enrichment was annotated with its nearest active enhancer using BEDOPS 39 . Regions of differential H3K4me1 signal within 1kb of each group of condition-specific enhancers were counted. Enrichment assessed as described below under statistics.
Overlap of CEBPA Peaks with Condition-Specific Enhancers
We used publicly available genome-wide positions of all GMP CEBPA ChIP-seq peaks 15 . CEBPA peaks overlapping each group of condition-specific enhancers were identified using the mergePeaks command in HOMER with the -cobound option. CEBPA peaks associated with each group of condition-specific enhancers were counted and enrichment assessed as described below under statistics Enhancer Overlap using BEDTools Published human CEBPA AML DNase sensitivity peaks 26 and enhancers 18 were compared with mouse CSF3R/CEBPA-specific enhancers. The coordinates for mouse enhancers converted to human coordinates using the UCSC liftover tool. Overlap was assessed using the BEDTools fisher test 38 . Enrichment of overlap is detected using a fisher's exact test with a significant right-sided p value while depletion is detected with a significant left-sided p value.
Quantification and Statistical Analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using Prism software (Version 7.0; Prism Software Corp.) or RStudio. Statistical analyses are described in figure legends. All data were analyzed with either an unpaired Student's t test, or ANOVA followed by post hoc analysis using a Sidak's corrected t test. For Taqman based array, microarray and RNA-seq data, p values were adjusted for repeated testing using a false discovery rate by the method of BenjaminiHochberg 45 . For enhancer enrichment analyses, a c 2 analysis was utilized with individual p-values adjusted by the method of Holm-Bonferroni. Survival analysis was conducted using the method of Kaplan-Meier and statistical significance was assessed using a Log Rank test.
Data Availability
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